KAZIA THERAPEUTICS

A Diversified, Clinical-Stage Oncology Drug Development Company

EVT-801: A clinical stage, first-in-class small molecule targeting tumor (lymph)-angiogenesis

Non-confidential deck

March 2024

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; the timely availability of necessary capital to pursue our business objectives; and our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services and other factors.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to clinical trial outcomes, sales, partnerships, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, or marketing existing products.

In addition, the extent to which the COVID-19 outbreak continues to impact our workforce and our discovery research, supply chain and clinical trial operations activities, and the operations of the third parties on which we rely, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels)



Oral Presentation

Administered by mouth once or twice daily

Strong IP Protection

Composition-of-matter to 2032 / 2033 in most jurisdictions

Low Cost of Goods

Straightforward manufacture with excellent stability

Favourable Preclinical Toxicology

Limited evidence of toxicity in one-month GLP studies

In Clinical Development

Currently undergoing Phase 1 clinical trial in Europe

KAZIA THERAPEUTICS

Targeting angiogenesis is a well-established approach in the treatment of cancer

Product	Company	Target	Indications	Annual Sales (US$)*
AVASTIN bevacizumab 100 MG/4 ML INJECTION FOR IV USE	Genentech A Member of the Roche Group	VEGF-A	• Colorectal cancer • Lung cancer • Breast cancer • Other cancers	**$7 billion**
Nexavar (sorafenib) tablets	BAYER	VEGFRs PDGFRs RAF kinases	• Hepatocellular carcinoma • Renal cell carcinoma • Thyroid cancer	**$1 billion**
SUTENT capsules sunitinib malate	Pfizer	VEGFRs PDGFRs	• Renal cell carcinoma • Gasto-intestinal stromal tumour	**$750 million**
Votrient pazopanib tablets (200 mg)	NOVARTIS	VEGFRs PDGFRs c-Kit FGFRs	• Renal cell carcinoma • Soft tissue sarcoma	**$1 billion**
Inlyta axitinib 1mg and 5mg tablets	Pfizer	VEGFRs c-Kit PDGFRs	• Renal cell carcinoma	**$400 million**

*approximate, based on company filings and market data

Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges

Angiogenesis inhibitors work by reducing the formation of **new blood vessels** around the tumour, starving it of vital nutrients needed for tumour growth, and limiting its ability to spread elsewhere in the body



1

Tumour Hypoxia

Sustained tumour hypoxia activates adaptive mechanisms, leading to secondary resistance and tumour progression

→ **Limited Duration of Effect**

2

Off-Target Activity

Most small molecule angiogenesis inhibitors have a broad range of pharmacological activities, leading to substantial toxicity (e.g. hypertension proteinuria & hand-foot syndrome)

→ **Significant Side Effects**

KAZIA THERAPEUTICS

EVT801: A differentiating anti-tumour approach



1

Inhibition of tumour escape and metastasis

- Stabilisation of tumour vasculature
- Inhibition of (lymph)-angiogenesis
- Avoidance of hypoxia decreases potential for metastatic spread

2

Increase in anti-tumour immune activity

- No impact on T-cells viability
- Increased infiltration of effector T-cells
- Reduction in immunosuppressive myeloid cells

3

Tumour Killing

- Direct effect on VEGFR3-expressing tumour cells (typically from endothelial origin, e.g. sarcoma)

KAZIA THERAPEUTICS

EVT801 selectively inhibits VEGFR3



EVT801 has a unique mode of action compared to angiokinase inhibitors

Unique mode of action:

Characteristics	EVT801	Angiokinase inhibitors
Blood vessel normalization	• **Tumour blood vessel normalization through avoidance of hypoxia** decreases potential for metastatic spread	• Tumour escape due to only transient tumour blood vessel normalization inducing hypoxia
Immune activity	• **No impact on CD3⁺ T-cells proliferation** • **Reduction in immunosuppressive cells** (CD45+ PDL1+ & M2) • **Increase in pro-inflammatory macrophages** (M1)	• Inhibition of CD3⁺ T-cell proliferation • Increase in immunosuppressive cells • Decrease of pro-inflammatory macrophages (M1)

Safety:

EVT801 does not induce hypertension in telemetered rats unlike sorafenib

- EVT801 does not induce any significant hypertension even after administration of 500mg/kg
- A singe administration of sorafenib from 10mg/kg produces dose-dependant and long-lasting increases in mean arterial pressure with a rapid onset of action

EVT801



Sorafenib



Current anti-VEGF agents have limitations

Target characteristic	EVT801	Multi-VEGF inhibitors
Potent small molecule VEGFR3 inhibitor	✓	✓
High selectivity over other VEGF receptors and TK panel	✓	X
Orally available	✓	✓
Effective as single agent in high VEGFR3 expression models	✓	✓
Potential companion diagnostic	✓	X
Equipotent to sorafenib	✓	✓
Reduced hypoxia/necrosis	✓	X
Well-tolerated in animal models	✓	✓
Reduce macrophage infiltration	✓	X
No inhibition of T cell function	✓	X
Potential for orphan status	✓	✓
Inhibits lymphangiogenesis	✓	X

	Cellular *in vitro* IC_{50} (nM)	
Compound	VEGFR2	VEGFR3
EVT801	**241**	**21**
EVT801 metabolite	**424**	**37**
Lenvatinib	58	390
Fruquintinib	568	2,097

- **More potent on VEGFR3** than second generation mTKIs
- **High cellular activity on VEGFR3** compared to key competitor compounds
- Active as single agent in range of models **without inducing hypoxia**
- Selective over GPCRs, ion channels, kinases
- **Negative** for Cytotoxicity, Ames, hERG, Cyp inhibition

Unlike many mTKIs, EVT801 does not inhibit CD3$^+$ T-cell function



- Sorafenib and axitinib inhibit T-cell proliferation
- **EVT801 and its metabolite have no negative impact on T-cell viability and proliferation** (as well as Lenvatinib)

Preclinical data confirms activity of EVT801 (1/2)

Dramatic single-agent activity in DEN-induced Hepatocellular carcinoma model

Experimental Methods

- Syngeneic mouse model
- HCC chemically induced with diethylnitrosamine (DEN)
- Treatment with EVT801 in M10-M12

Conclusions

- EVT801 monotherapy causes marked reduction in growth of primary tumour versus untreated comparator
- EVT801 appears to have significant anti-metastatic effect

Tumour Growth

Total Tumour Volume

85% reduction



Metastasis

Number of Tumours in the Liver

50% reduction



* Statistically significant ($p<0.05$)

Data on file

Preclinical data confirms activity of EVT801 (2/2)

Synergistic activity in combination with anti-CTLA4 mAb

Experimental Methods

- Orthotopic tumour mouse model
- 4T1 tumour cells inoculated in BALB/c mice (mammary fat pad)
- Treatment with EVT801 on D7-D21 and with anti-CTLA4 on D7, D14, D21

Conclusions

- EVT801 monotherapy has approximately equivalent activity to anti-CTLA4 antibody
- Combination of EVT801 and anti-CTLA4 antibody is highly synergistic



Data on file

Note: CTLA4 is the target of Yervoy® (ipilimumab), an approved immuno-oncology therapy

KAZIA THERAPEUTICS

Phase 1 dose-finding trial ongoing in France – KZA 0801-101: NCT05114668

Target population: Histologically-confirmed advanced or metastatic solid tumours, unresponsive to standard treatment, or for whom no standard treatment is available or appropriate



Clinical sites (France only) :

- IUCT-Oncopole, Toulouse - PI : Dr Gomez-Roca
- Centre Léon Bérard, Lyon – PI : Dr Philippe Cassier

Stage 2: RCC: renal cell carcinoma; STS: soft tissue sarcoma; High grade serous (HGS) ovarian cancer under consideration

MTD = Most Tolerated Dose ; RP2D = Recommended Phase 2 Dose

Exploratory biomarkers during Phase 1 clinical trial

EVT801 Biomarkers Strategy

1

Patient characterization based on VEGFR-3 /CAIX/CD8 expression on archival tissues and/or biopsies

- VEGFR-3 protein signature by histology
  - VEGFR-3/CAIX/CD8/CD31/PD-L1



VEGFR-3 & Resistance to PD-1 mAb mRNA signatures on archival tissues and/or biopsies:

- VEGFR-3 mRNA signature by Fluigdim
- PD-1 mAb resistance mRNA signature



2

Unbiased biomarker:

- Total RNA sequencing on blood cells at C1D1 vs CD2D1

3

Circulating endpoint biomarkers:

- Immunomonitoring based on CD8^{pos} T-cells /MDSC ratio
- Proteins signature based on chemokines involved in inflammation & angiogenesis



4

Safety biomarkers to control hypertension:

- Blood pressure measurement as EVT801 dose not induce hypertension in preclinical toxicology model.

5

Resting samples will include:

Frozen plasma, frozen whole blood, frozen PBMCs

KAZIA THERAPEUTICS

Status of Phase 1 Clinical Study: KZA 0801-101

EVT801 Clinical Study		
Protocol Number	**Study Name**	**Study Update**
KZA 0801-101	A Phase 1, First in Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients with Advanced Solid Tumours	To date 32 patients included in the study • 26 patients treated • 5 dosing cohorts completed up to 400mg BID • Actively enrolling patients in the 500mg BID cohort A number of patients have remained on treatment for two or more cycles with 7 reaching cycle 3 (one reaching Cycle 9) Biomarkers have shown strong VEGFR3 expression in some indications, and we have observed encouraging clinical activity in HGS* ovarian cancer patients (strongly expressing VEGFR3)

Stage 1 Clinical and Biomarker update accepted for presentation at AACR 2024, April 5-10, San Diego, California

*HGS: High grade serous

Key Points

1. Well-understood mechanism (anti-angiogenesis) with unique differentiating feature (high VEGFR3 selectivity)
2. Strong preclinical data package, with evidence of activity in multiple tumours and favorable toxicology
3. Potential for combination use with immuno-oncology therapies
4. Ongoing phase 1 clinical study demonstrating favorable safety and tolerability profile to date. Additional clinical and biomarker data accepted for presentation at AACR 2024
5. Encouraging signal of activity in HGS ovarian cancer as well as strong VEGFR3 biomarker expression in multiple indications
6. Anticipate Stage 1 completion 2Q 2024



KAZIA

THERAPEUTICS

www.kaziatherapeutics.com

info@kaziatherapeutics.com